==== Front Biomed Res Int Biomed Res Int BMRI BioMed Research International 2314-6133 2314-6141 Hindawi 10.1155/2020/3796792 Research Article Predicting Factors for Rapid Progressive Chronic Kidney Disease in Primary Glomerular Disease Patients with Moderate-to-Severe Stage Tan Jun Zhang Hao Zheng Wei Yang Shikun Yang Minghui https://orcid.org/0000-0001-7149-6013Liu Yan liuyanxy3yy@csu.edu.cn Department of Nephrology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, China Academic Editor: Yoshiyuki Morishita 2020 28 11 2020 2020 37967922 8 2020 28 10 2020 29 10 2020 Copyright © 2020 Jun Tan et al.2020This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Objective To investigate the predictive factors associated with rapid progressive chronic kidney disease (CKD) in patients with primary glomerular disease (PGD). Methods Baseline data, clinical biochemistry, laboratory data, and imaging data were collected from 112 PGD patients in CKD stages 3 and 4 who were hospitalized at the Third Xiangya Hospital. Patients were divided into rapid progression group (Group R) and no rapid progression group (NR) according to the definition of rapid progression of CKD. Results The age, systolic blood pressure (SBP), serum β2-microglobulin (sβ2-MG), urinary α1-microglobulin (uα1-MG), and cardiothoracic ratio (CTR) of the R group were significantly higher than the NR group. However, the size of the kidney, high-dense lipoprotein (HDL), hemoglobin (Hb), and hematocrit of the R group were significantly lower than the NR group (P < 0.05). Binary logistic regression analysis showed that baseline CTR, SBP, size of the kidney, and HDL were independent risk factors for rapid progression of PGD. At the end of follow-up, CTR and SBP of group R were higher than the NR group, and the size of the kidney and HDL of group R were lower than the NR group. Conclusion Increased baseline CTR and SBP and decreased baseline HDL and renal volume could be the predictors of rapid progression in patients of PGD at the CKD stages 3 and 4. ==== Body 1. Introduction A meta-analysis of 100 articles indicated that the average global prevalence rate of chronic kidney disease (CKD) is about 13.4%, among which the prevalence rate of CKD stages 1-5 is 3.5%, 3.9%,7.6%, 3.5%, and 0.1%, respectively [1]. The majority of CKD patients are in stages 3 and 4. Primary glomerular disease (PGD) is a kind of primary glomerular disease characterized by hematuria, proteinuria, edema, and hypertension. PGD is one of the common causes of end-stage renal disease (ESRD). ESRD patients would need renal replacement treatment, which brings patients and society economical and psychological burden. Previous studies showed that severe infection, acute heart failure, urinary tract obstruction, and hypovolemic shock may lead to acute-on-chronic renal injury and hyperuricaemia [2, 3]. High protein diet, genetic, and epigenetic variants are risk factors of rapid progression of CKD [4, 5]. Coresh et al. found that a 30% decline of estimated glomerular filtration rate (eGFR) within 2 years was associated with about 5-fold increased risk of ESRD after adjustment for covariates including baseline eGFR [3]. However, up to now, no biomarkers are available as predictors of rapid progression of CKD caused by PGD, which can help physicians perform more strict education and rigorous treatment in patients at the initial stage to avoid the unexpected consequence. Therefore, this study is aimed at identifying risk factors and predictors of rapid progression of CKD caused by PGD. Our results help establish a diagnostic standard of rapid progression of PGD with high sensitivity and specificity. 2. Materials and Methods 2.1. Patients This study was approved by the Ethics Committee of Third Xiangya Hospital, and no informed consent was required because this is a retrospective study. A total of 306 PGD patients were screened who were hospitalized at the nephrology department in the Third Xiangya Hospital from January 2014 to September 2016 and initially diagnosed as chronic CKD stages 3-4 caused by PGD. Patients were excluded if they met the exclusion criteria: (1) patients who have been treated with renal replacement therapy (n = 11); (2) patients suffering severe infection, cardiovascular, cerebrovascular disease, liver failure, and respiratory failure (n = 63); (3) patients using hormones or immunosuppressants (n = 15); (4) patients who did not participate regularly follow-up examination for 2 years (n = 61); (5) Patients with missing data > 20% (n = 44). Finally, 112 eligible patients were included in this study. 2.2. Diagnosis The standard diagnosis of PGD conformed to the definition of 2012 KDIGO guidelines for glomerulonephritis. The standard diagnosis of hypertension: SBP ≥ 130 mmHg and (or) diastolic blood pressure (DBP) ≥ 80 mmHg according to America College of Cardiology/American Heart Association in 2017. The standard diagnosis of diabetes: the history of diabetes, fast plasma glucose (FPG) ≥ 7.0 mmol/L, or 2 hours postprandial blood glucose (PBG) ≥ 11.1 mmol/L, or random blood glucose (RBG) ≥ 11.1 mmol/L. The standard diagnosis of rapid progressive primary glomerular disease (PGD): reduction in eGFR of at least 30% from baseline within 2 years and/or commencement of dialysis. 2.3. Data Collection The baseline data were collected from the patients, including age, sex, body mass index (BMI), basal metabolic rate (BMR), mean arterial pressure (MAP), size and lesion of parenchyma of kidney testing by ultrasound, cardiothoracic ratio (CTR) obtained by chest X-ray and serum indicators such as hemoglobin (Hb), creatinine (Cr), blood urea nitrogen (BUN), potassium (K), chlorine (Cl), albumin (Alb), total cholesterol (TC), cystatin C (CysC), factor B, homocysteine (Hcy), ceruloplasmin (CP), and urinary indicators such as uACR, uβ2-MG, and uRBP. The eGFR was calculated with the formula modified for Chinese: GFR = 169 × (Cr/88.4)−0.608 × CysC−0.63 × Age−0.157(×0.83 if female) [6]. The parenchyma, the length, and diameter of the kidney were evaluated by B-ultrasound. We categorized renal parenchyma into I to IV: the renal parenchyma density less than liver (I), the renal parenchyma density is equal to liver (II), the renal parenchyma density slightly higher than liver (III), and the renal parenchyma density higher than liver (IV). CTR was classified into three levels: 0 (CTR < 0.52), 1 (0.52 ≤ CTR < 0.55), 2 (0.55 ≤ CTR < 0.6), and 3 (CTR ≥ 0.6). Over 30% reduction of eGFR in 2 years was chosen as an endpoint for the rapid progression of CKD caused by PGD, and the patients were divided into rapid progression group (R) and no rapid progression group (NR). The standards of the acceptable blood pressure (BP) and hemoglobin in PGD patients were as follows: BP ≤ 130/80 mmHg, and Hb ≥ 130 g/L in male (or 120 g/L in female) according to KDIGO guidance on anemia. 2.4. Statistical Analysis Data in normal distribution were expressed as mean ± SD and compared by ANOVA and t-test. Data not in normal distribution were expressed as median (25th to 75th percentiles) and compared by nonparametric test (Wilcoxon rank-sum test). Qualitative variables were expressed as percentages and compared by the Chi-square test. Logistic regression analysis was used to identify risk factors and predictors. P < 0.05 indicated statistical significance. 3. Results A total of 112 patients (average age of group NR and group R were 51.62 ± 16.68 and 58.27 ± 12.92 years, respectively) with CKD caused by PGD participated in the study, including 60 males and 52 females. According to the stage of CKD, there were 52 patients in stage 3 and 60 patients in stage 4. After the 2-year follow-up, there were 18 patients in stages 1-2, 21 patients in stage 3, 35 patients in stage 4, and 38 patients in stage 5, which indicated that most patients have entered into end-stage within 2 years. Univariate analysis showed that age, SBP, sβ2-MG, uα2-MG, and CTR were significantly higher in the R group than in the NR group, while the kidney size, HDL, Hb, and Hct were significantly lower in the R group than in the NR group (P < 0.05). Other factors showed no significant differences between the two groups such as diabetes history, CRP, LDL-C, TC, TG, ESR, CP, prealbumin (PA), Alb, ferritin, transferrin, α1-MG, RBP, serum β-d-glucosaminidase (sNAG), and urinary β-d-glucosaminidase (uNAG) (Tables 1 and 2). Binomial logistic regression analysis revealed that CTR, SBP, kidney size, and HDL were independent risk factors for the rapid progression of PGD (Table 3). The standard regression formula was logit(P) = 1.559 × CTR + 0.042 × SBP − 1.620 × HDL − 0.007 × (kidney size) − 10.296 (P < 0.001, R2 = 0.401). To test the predictive performance of the regression formula, we constructed a receiver operating characteristic (ROC) curve (Figure 1). The area under the ROC curve (AUC) was 0.877, and the specificity and sensitivity were 0.797 and 0.842, respectively. After the 2-year follow-up, we found that SBP and CTR of the R group were significantly higher than baseline, while renal volume and HDL were lower than baseline (P < 0.05). However, such changes were not observed in the NR group. At the end of the follow-up, CTR and SBP were significantly higher, and HDL was significantly lower in the R group than in the NR group (Table 4). In different CKD stages, the change of corresponding indicators was observed (Table 5). In the patients with CKD stage 3, CTR, and SBP at the endpoint were significantly higher than the baseline (P < 0.05), HDL significantly decreased compared with the baseline, and the baseline and renal volume of follow-up cases did not show significant differences. In patients with CKD stage 4, the follow-up endpoints CTR and SBP increased significantly, and the renal volume and HDL decreased significantly compared to the baseline value (P < 0.05). At the baseline, BP reaching threshold (BP < 130/80 mmHg) was about 34%. At the endpoint, BP reaching threshold was 25.3%. The qualified rate of BP control in the R group dropped from 20% to 13%. 4. Discussion It is generally acknowledged that CTR directly reflects cardiac size, relating to cardiac failure [7, 8]. This retrospective cohort study is aimed at exploring biomarkers as the predictors of rapid progression of CKD caused by PGD. For the first time, we found that CTR > 0.5 was the risk factor and predictor of the rapid process of CKD caused by PGD in the patients with CKD stages 3-4. The increase of CTR correlates with age, BMI, coronary artery stenosis, and impairment of left ventricular function [7]. CTR was significantly related to target organ injury in patients with hypertension [8]. A large sample study on the CKD population showed that all-cause mortality occurred in 28.5% of patients with normal CTR (≤0.50) and 34.3% of patients with high CTR (>0.50) [9]. Compared with baseline values, we found that more patients with PGD had increased CTR at the endpoint. It may correlate with the accumulation of toxins, anemia, and unmanageable blood pressure [10]. The mechanism needs further investigation. Therefore, CTR is critical for patients with CKD caused by PGD, and it is necessary to constantly monitor CTR to facilitate timely intervention. Some studies suggested that hypertension with renal failure is more difficult to control, and the risk of cardiovascular disease significantly increases [11, 12]. Indeed, SBP is an independent risk factor of the rapid progress of CKD. Compared with DBP, SBP shows a stronger ability in predicting the occurrence of ESRD events [13, 14]. With the progress of CKD, increased salt and water retention, excessive activation of the renin-angiotensin-aldosterone system, and higher level of sympathetic activation with decreasing eGFR would contribute to uncontrolled SBP [15, 16]. Our study revealed that SBP is the risk factor and predictor of the rapid progress of CKD caused by PGD. At the endpoint, the SBP of patients in the R group was higher than the baseline, and the qualified rate of BP control in the R group dropped from 20% to 13%. It was reported that CKD would rapidly progress when SBP < 110 mmHg, especially in the later period of CKD without albuminuria [17]. Therefore, it is necessary to require patients to monitor their blood pressure regularly, control the lifestyle, and take an individualized antihypertensive approach. Current evidence indicates that dyslipidemia is closely related to the occurrence and progress of CKD. The mechanism of abnormal blood lipids affecting kidney diseases is manifold and is related to oxidative stress, proteinuria, and lipoprotein transport disorders [18]. In kidney diseases, dyslipidemia is usually manifested in elevated TG, diminished HDL, and elevated LDL. HDL-C has antioxidant and anti-inflammatory effects [19]. In CKD patients, HDL reduced cholesterol efflux capacity in macrophages, the ability of antioxidant, and anti-inflammatory actions [20]. Moreover, lipolysis efficiency decreased with a reduction in eGFR [21]. Kawachi et al. found that a low serum HDL-C level could be a significant predictor of CKD progression, especially in female patients with CKD under 70 years of age [22]. Bowe et al. reported that compared to those with HDL-C of 40 mg/dl or more, low HDL-C (under 30 mg/dl) was associated with the increased risk of incident eGFR under 60 ml/min/1.73 m [23]. Our study showed that decreased baseline HDL was the predictor of rapid progression of CKD3-4 caused by PGD. Renal function may decline rapidly with parenchymal lesions and nephrons loss. In addition, the kidney size is proportional to the number of nephron and is significantly associated with renal function [24]. Therefore, the decline in renal function can be judged to some extent by the change in kidney size [25]. In our study, we observed that baseline renal volume was the independent predictor of rapid progression of PGD during two years by using body surface area to correct the size of the kidney. In addition, there were 18 patients in stages 1 and 2 after the 2-year follow-up. This is a remarkable finding. There is a possibility of renal function recovery in the early stages of disease, or there are some factors that affect the SCr and eGFR when they are tested, such as diet, exercise, and medicine. Our study has some limitations. While we showed that 4 parameters (CTR, SBP, HDL, and renal volume) could be the predictors of rapid progression of PGD, it remains to decide whether the presence of a single parameter is important or complete the set of 4 parameters is indispensable for the prediction. In conclusion, increased baseline CTR and SBP and decreased baseline HDL and renal volume could be the predictors of rapid progression of PGD in patients of PGD at the CKD stages 3 and 4. Data Availability All data are available upon request to correspondence author. Conflicts of Interest Lei Mo was employed by Shanghai Lejiu Healthcare Technology Co., Ltd. The remaining authors declare no conflicts of interest. Authors' Contributions Jun Tan, Hao Zhang, Wei Zheng, Lei Mo, Shikun Yang, and Minghui Yang collected and analyzed clinical data. Yan Liu designed and supervised the study. Figure 1 ROC curve of independent risk factors. Table 1 Clinical characteristics of the study population at baseline. Indicators Group NR (n = 70) Group R (n = 42) P Age (years) 51.62 ± 16.68 58.27 ± 12.92 0.031 Gender Female 32 (45.7%) 20 (47.6%) 0.95 Male 38 (54.3%) 22 (52.4%) BMI (kg/m2) 23.01 ± 3.48 23.68 ± 3.95 0.36 Blood pressure SBP (mmHg) 129.96 ± 17.42 140.15 ± 17.01 0.002 DBP (mmHg) 78.69 ± 11.0 79.12 ± 11.07 0.85 MAP (mmHg) 95.87 ± 12.22 99.51 ± 11.61 0.13 Antihypertensive drugs No-antihypertensive treatment 45 (64.3%) 26 (61.9%) 0.94 Antihypertensive treatment 25 (35.7%) 16 (38.1%) Diabetes history No 64 (91.4%) 33 (78.6%) 0.09 Yes 6 (8.6%) 9 (21.4%) Table 2 Laboratory and imaging characteristics of the study population at baseline. Indicators Group NR (n = 70) Group R (n = 42) P Renal function Baseline eGFR (mL/min·1.73 m2) 31.05 (16.01, 41.18) 23.35 (17.40, 41.64) 0.80 ΔeGFR (mL/min·1.73 m2) 1.466 (-4.738, 4.646) 15.302 (8.824, 22.694) 0.000 CysC (mg/L) 1.99 ± 0.75 2.24 ± 1.22 0.17 UA (mmol/L) 455.08 ± 127.31 442.57 ± 117.2 0.60 Blood routine, urine routine WBC (∗1012/L) 7.7 ± 2.84 7.81 ± 3.34 0.86 Hb (g/L) 114.53 ± 24.47 105.72 ± 27.7 0.014 Hct (%) 34.75 ± 7.03 31.45 ± 6.97 0.020 uSG 1.02 (1.015, 1.02) 1.02 (1.015, 1.02) 0.80 uPH 5.5 (5.0, 6.0) 6 (5.38, 6.50) 0.62 Lipid TC (mmol/L) 5.21 (4.06, 6.41) 4.40 (3.83, 5.56) 0.19 TG (mmol/L) 1.71 (1.0, 2.66) 1.63 (1.28, 2.57) 0.74 LDL-C (mmol/L) 2.64 (2.06, 3.37) 2.28 (1.97, 2.82) 0.37 HDL-C (mmol/L) 1.28 (0.97, 1.62) 1.2 (0.90, 1.37) 0.024 Electrolyte K (mmol/L) 4.04 ± 0.57 4.14 ± 0.7 0.43 Na (mmol/L) 140 ± 3.26 140.01 ± 4.09 0.98 Cl (mmol/L) 105.81 ± 4.59 106.52 ± 5.09 0.44 CO2CP (mmol/L) 21.38 ± 3.94 21.19 ± 5.44 0.83 Ca (mmol/L) 2.15 ± 0.25 2.15 ± 0.19 0.99 IP (mmol/L) 1.16 ± 0.23 1.26 ± 0.4 0.09 Nutrition index Alb (g/L) 36.9 (32.95, 41.68) 34.55 (30.50, 38.08) 0.28 Fe (umol/L) 17.53 ± 8.69 15.61 ± 9.9 0.28 Transferrin (g/L) 2.09 ± 0.63 1.9 ± 0.65 0.13 PA (g/L) 244.36 ± 74.48 265.64 ± 94.59 0.22 Inflammatory index CP (mg/L) 330.37 ± 188.62 326.6 ± 137.53 0.91 ESR (mm/hr) 31 (21, 57) 58.50 (30.50, 73.50) 0.06 CRP (mg/L) 1.9 (0.4, 7.36) 1.40 (0.70, 5.18) 0.71 Glomerular function sα1-MG (mg/L) 55.04 ± 20.58 55.71 ± 23.93 0.87 sβ2-MG (mg/L) 6.22 ± 3.41 8.42 ± 6.49 0.021 sRBP (mg/L) 60.9 ± 81.13 51.36 ± 56.26 0.50 BF (mg/L) 323.37 ± 95.19 292.68 ± 164.87 0.21 Hcy (umol/L) 19.65 (11.75, 24.58) 17.60 (9.75, 26.40) 0.16 sNAG (U/L) 24.95 ± 28.21 23.57 ± 13.55 0.77 Renal tubular function uβ2-MG (μg/mL) 0.63 (0.15, 4.43) 2.20 (1.06, 4.44) 0.52 umicroAlb (mg/L) 264.1 (85.6, 631.5) 267.20 (138.15, 572.25) 0.89 uα1-MG (μg/mL) 14.45 (8.55, 24.88) 19.80 (9.15, 39.70) 0.033 uRBP (mg/L) 6.13 (1.87, 9.48) 6.99 (2.97, 13.00) 0.49 uNAG (U/L) 9.4 (5.1, 17.75) 8.50 (4.75, 19.20) 0.79 uACR (mg/L) 39.34 (8.63, 106.67) 80.73 (19.25, 154.36) 0.036 Kidney size (cm3/m2) 162.58 ± 72.27 149.71 ± 64.91 0.035 Renal parenchyma I 3 (4.3%) 2 (4.8%) 0.037 II 25 (35.7%) 8 (19%) III 7 (10%) 6 (14.3%) IV 35 (50%) 26 (61.9%) CTR 0.51 ± 0.05 0.53 ± 0.06 0.049 Alb: albumin; BF: B factor; Ca: Calcium; Cl: chlorine; CO2CP: carbon dioxide binding force; CP: Copper blue protein; CTR: cardiothoracic ratio; CysC: cystatin C; eGFR: estimated glomerular filtration rate; Hb: hemoglobin; Hct: hematocrit; Hcy: homocysteine; HDL-C: high-density lipoprotein cholesterol; IP: phosphorus; K: potassium; LDL-C: low-density lipoprotein cholesterol; Na: sodium; PA: prealbumin; S α1-MG: blood α1 microglobulin; S β2-MG: blood β2 microglobulin; SRBP: Schromatol protein; TC: total cholesterol ester; TG: total triglycerides; UA: uric acid; UACR: ratio of urinary albumin creatinine; umicroAlb: urinary microalbumin; USG: urine gravity; Uα1-MG: urine α1 microglobulin; Uβ2-MG: urine β2 microglobulin; WBC: white blood cell count. Table 3 Independent risk factors for rapid progression of renal function in patients with PGD. Index B P value OR 95% CI for OR CTR 1.559 0.004 5.943 1.185 9.802 SBP 0.042 0.006 1.043 1.012 1.075 HDL -1.620 0.024 0.198 0.048 0.817 Kidney volume -0.007 0.042 0.907 1.000 1.013 Table 4 Baseline and follow-up case of not rapid progression group and rapid progression group. Variates Baseline Endpoint t/x2 P CTR NR group 0.51 ± 0.04 0.51 ± 0.038 2.172 0.05 R group 0.53 ± 0.065 0.58 ± 0.054a 3.176 0.005 SBP NR group 130.23 ± 17.2 129.75 ± 17.21 1.200 0.24 R group 140.33 ± 16.8 148.42 ± 18.31a 3.030 0.005 HDL NR group 1.24 (0.94, 1.44) 1.25 (0.98, 1.5) -1.736 0.09 R group 1.21 (0.91, 1.34) 1.1 (0.96, 1.19)a 4.534 0.005 Kidney volume NR group 162.19 ± 83.53 157.99 ± 83.39 0.673 0.51 R group 175.78 ± 53.84 134.60 ± 74.24 3.033 0.007 aCompared with the group NR at the follow-up endpoint, P < 0.05. Table 5 Baseline and follow-up case of indicators in different CKD stage. Index CKD stage 3 (n = 52) Baseline Follow-up endpoint P value CTR 0.52 ± 0.05 0.53 ± 0.046 0.028 SBP 129.78 ± 14.77 136.76 ± 19.70 0.035 HDL 1.33 (1.04, 1.55) 1.31 (1.03, 1.44) 0.043 Kidney volume 156.33 ± 59.62 145.56 ± 52.94 0.21 Index CKD stage 4 (n = 60) Baseline Follow-up endpoint P value CTR 0.51 ± 0.054 0.53 ± 0.05 0.008 SBP 136.42 ± 17.15 140.49 ± 22.72 0.049 HDL 1.07 (0.89, 1.28) 1.05 (0.84, 1.15) 0.037 Kidney volume 185.32 ± 83.02 151.99 ± 99.85 0.019 ==== Refs 1 Hill N. R. Fatoba S. T. Oke J. L. Global prevalence of chronic kidney disease –a systematic review and meta-analysis PLOS ONE 2016 11 7 10.1371/journal.pone.0158765 2-s2.0-84978128484 27383068 2 Tovar-Palacio C. Tovar A. R. Torres N. Proinflammatory gene expression and renal lipogenesis are modulated by dietary protein content in obese Zucker fa/fa rats Renal Physiology 2011 300 1 F263 F271 10.1152/ajprenal.00171.2010 2-s2.0-78651282148 20962115 3 Coresh J. Turin T. C. Matsushita K. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality Journal of the American Medical Association 2014 311 24 2518 2531 10.1001/jama.2014.6634 2-s2.0-84902826499 24892770 4 Ma Y.-C. Zuo L. Chen J.-H. Improved GFR estimation by combined creatinine and cystatin C measurements Kidney International 2007 72 12 1535 1542 10.1038/sj.ki.5002566 2-s2.0-36649020633 17898698 5 Ernst E. R. Shub C. Bailey K. R. Brown L. R. Redfield M. M. Radiographic measurements of cardiac size as predictors of outcome in patients with dilated cardiomyopathy Journal of Cardiac Failure 2001 7 1 13 20 10.1054/jcaf.2001.23244 2-s2.0-0035068102 11264545 6 Kearney M. T. Fox K. A. Lee A. J. Predicting sudden death in patients with mild to moderate chronic heart failure Heart 2004 90 10 1137 1143 10.1136/hrt.2003.021733 2-s2.0-4644232888 15367507 7 Wang Y. Zhang L. Li X. Improvement of awareness, treatment and control of hypertension among chronic kidney disease patients in China from 1999 to 2005 Hypertension Research 2009 32 6 444 449 10.1038/hr.2009.38 2-s2.0-68249150863 19494816 8 Bolignano D. Pisano A. D'Arrigo G. Pulmonary hypertension: a neglected risk condition in renal patients? Reviews in Cardiovascular Medicine 2018 19 4 117 121 10.31083/j.rcm.2018.04.3188 2-s2.0-85065794298 31064162 9 Giamouzis G. Sui X. Love T. E. Butler J. Young J. B. Ahmed A. A propensity-matched study of the association of cardiothoracic ratio with morbidity and mortality in chronic heart failure The American Journal of Cardiology 2008 101 3 343 347 10.1016/j.amjcard.2007.08.039 2-s2.0-38849195675 18237597 10 Chen K. H. Lin-Tan D. T. Huang W. H. Cardiothoracic ratio, malnutrition, inflammation, and two-year mortality in non-diabetic patients on maintenance hemodialysis Kidney and Blood Pressure Research 2008 31 3 143 151 10.1159/000127388 2-s2.0-46249109803 18424899 11 Sakhuja A. Textor S. C. Taler S. J. Uncontrolled hypertension by the 2014 evidence-based guideline: results from NHANES 2011-2012 Journal of hypertension 2014 33 3 44 51 12 Thomas G. Xie D. Chen H.-Y. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney Disease Hypertension 2016 67 2 387 396 10.1161/HYPERTENSIONAHA.115.06487 2-s2.0-84954402734 26711738 13 Bowman T. S. Gaziano J. M. Kase C. S. Sesso H. D. Kurth T. Blood pressure measures and risk of total, ischemic, and hemorrhagic stroke in men Neurology 2006 67 5 820 823 10.1212/01.wnl.0000233981.26176.e1 2-s2.0-33748698275 16966544 14 Inoue R. Ohkubo T. Kikuya M. Stroke risk of blood pressure indices determined by home blood pressure measurement the Ohasama study Stroke 2009 40 8 2859 2861 10.1161/STROKEAHA.108.546499 2-s2.0-68749117702 19478224 15 Townsend R. R. Taler S. J. Management of hypertension in chronic kidney disease Nature Reviews. Nephrology 2015 11 9 555 563 10.1038/nrneph.2015.114 2-s2.0-84940452310 26215512 16 Klein I. H. Ligtenberg G. Neumann J. Sympathetic nerve activity is inappropriately increased in chronic renal disease Journal of the American Society of Nephrology 2003 14 12 3239 3244 10.1097/01.ASN.0000098687.01005.A5 2-s2.0-0344236401 14638922 17 Zheng Y. Cai G. Y. Chen X. M. Prevalence, awareness, treatment, and control of hypertension in the non-dialysis chronic kidney disease patients Chinese Medical Journal 2013 126 12 2276 2280 23786938 18 Trevisan R. Dodesini A. R. Lepore G. Lipids and renal disease Journal of the American Society of Nephrology 2006 17 4 supplement 2 S145 S147 10.1681/ASN.2005121320 2-s2.0-33645469406 16565240 19 Vaziri N. D. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease Journal of Renal Nutrition 2010 20 5 S35 S43 10.1053/j.jrn.2010.05.010 20797569 20 Kaseda R. Jabs K. Hunley T. E. Dysfunctional high-density lipoproteins in children with chronic kidney disease Metabolism 2015 64 2 263 273 10.1016/j.metabol.2014.10.020 2-s2.0-84920581215 25467845 21 Ćwiklińska A. Cackowska M. Wieczorek E. Progression of chronic kidney disease affects HDL impact on lipoprotein lipase (LPL)-mediated VLDL lipolysis efficiency Kidney and Blood Pressure Research 2016 43 3 970 978 22 Kawachi K. Kataoka H. Manabe S. Mochizuki T. Nitta K. Low HDL cholesterol as a predictor of chronic kidney disease progression: a cross-classification approach and matched cohort analysis Heart and Vessels 2019 34 9 1440 1455 10.1007/s00380-019-01375-4 2-s2.0-85063063771 30874893 23 Bowe B. Xie Y. Xian H. Balasubramanian S. al-Aly Z. Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression Kidney International 2016 89 4 886 896 10.1016/j.kint.2015.12.034 2-s2.0-84964691547 26924057 24 Kariyanna S. S. Light R. P. Agarwal R. A longitudinal study of kidney structure and function in adults Nephrology Dialysis Transplantation 2010 25 4 1120 1126 10.1093/ndt/gfp654 2-s2.0-77950228237 25 Sanusi A. A. Arogundade F. A. Famurewa O. C. Relationship of ultrasonographically determined kidney volume with measured GFR, calculated creatinine clearance and other parameters in chronic kidney disease (CKD) Nephrology Dialysis Transplantation 2009 24 5 1690 1694 10.1093/ndt/gfp055 2-s2.0-65249093637